Centessa Pharmaceuticals' (CNTA) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reiterated their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Free Report) in a research note published on Wednesday morning,Benzinga reports. Guggenheim currently has a $28.00 price objective on the stock.

Several other brokerages have also recently commented on CNTA. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $26.00.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock traded up $0.08 during mid-day trading on Wednesday, hitting $14.59. 620,346 shares of the stock traded hands, compared to its average volume of 548,232. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company's 50-day simple moving average is $16.48 and its 200-day simple moving average is $16.42. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of 1.54.

Remove Ads

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the transaction, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total value of $867,350.00. Following the sale, the chief executive officer now owns 429,398 shares of the company's stock, valued at approximately $6,771,606.46. The trade was a 11.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,168 shares of company stock valued at $4,309,568. Insiders own 11.59% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $31,000. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC lifted its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at about $171,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.